Erkul Kozmetik failed to test talc in OTC drugs for identity and asbestos, violating manufacturing rules.
What happened
FDA reviewed records the company submitted after an August 25, 2025 request under section 704(a)(4) of the FD&C Act, not an inspection. The records showed the firm did not test incoming talc for identity and did not show appropriate asbestos testing for all lots used; the firm’s quality unit approved talc with incomplete specifications. FDA also said import records showed the firm shipped drug products to the U.S. in 2025 after saying it had not shipped after December 2024, and FDA placed the firm on import alert on March 17, 2026.
What FDA found
The firm did not test each incoming component lot for identity and conformity with written purity, strength, and quality specifications; it did not test talc for identity and did not show appropriate asbestos testing for all lots used.
21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)The quality control unit approved talc with incomplete specifications and did not ensure test procedures and specifications were scientifically sound; the talc specifications lacked assay, impurity limits, molds and yeasts limits, and an asbestos absence test.
21 CFR 211.22; 21 CFR 211.160(b)The firm’s talc specifications were incomplete compared with the current USP talc monograph, which includes an asbestos test.
FD&C Act section 501(b)
What FDA wants
FDA asks the firm to correct the violations promptly and respond in writing within 15 working days. It also asks for identity, assay, and impurity results for talc lots or asbestos testing of retained finished product within 30 calendar days, plus a risk assessment for in-date products and a quality-unit remediation plan.
Who should pay attention
- brands that buy OTC drugs from this contract manufacturer
- companies sourcing talc-containing drug products
- U.S. importers and distributors of OTC drugs
This is a summary. Read the original letter on fda.gov.